Leerink Partnrs Has Positive Estimate for RXRX Q2 Earnings
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) – Equities research analysts at Leerink Partnrs increased their Q2 2025 earnings per share (EPS) estimates for shares of Recursion Pharmaceuticals in a report issued on Tuesday, June 10th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($0.27) per share for the quarter, up […]
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) – Equities research analysts at Leerink Partnrs increased their Q2 2025 earnings per share (EPS) estimates for shares of Recursion Pharmaceuticals in a report issued on Tuesday, June 10th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($0.27) per share for the quarter, up […]
